{
  "ticker": "LLY",
  "target_date": "2024-12-18",
  "actual_date": "2024-12-18",
  "collected_at": "2025-12-08T11:09:55.253787",
  "price": {
    "open": 769.26,
    "high": 773.23,
    "low": 756.85,
    "close": 759.0484008789062,
    "volume": 3354200,
    "change_1d_pct": -1.79,
    "change_7d_pct": -4.84,
    "change_30d_pct": -4.97
  },
  "technicals": {
    "rsi_14": 40.42,
    "sma_20": 782.54,
    "sma_50": 820.93,
    "macd": -9.556,
    "macd_signal": -8.957,
    "macd_histogram": -0.599,
    "bb_upper": 832.47,
    "bb_lower": 732.61,
    "price_vs_sma20_pct": -3.0,
    "price_vs_sma50_pct": -7.54,
    "volume_ratio": 0.94
  },
  "fundamentals": {
    "market_cap": 891042201600,
    "pe_ratio": 48.699657,
    "forward_pe": 43.86408,
    "price_to_book": 37.423195,
    "price_to_sales": 14.995712,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.61,
    "pct_from_52w_low": 59.34
  },
  "macro": {
    "spy": {
      "price": 579.24,
      "change_1d_pct": -2.98,
      "change_7d_pct": -2.74
    },
    "vix": {
      "level": 27.62,
      "signal": "HIGH_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.49
    },
    "dollar_index": {
      "level": 108.03
    },
    "gold": {
      "price": 2636.5
    },
    "regime": "BEAR_HIGH_VOL"
  },
  "news": [
    {
      "headline": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "source": "MarketWatch",
      "datetime": 1734539580,
      "summary": "Eli Lilly & Co. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=a0e2fae7f8aff859095c5cf1a1a2261d9b357f5b66213b8dfc4c49ac5a9ac066"
    },
    {
      "headline": "Merck Licenses a Weight-Loss Pill. It\u2019s Bad News for Obesity Biotechs.",
      "source": "Yahoo",
      "datetime": 1734535500,
      "summary": "The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk\u2019s dominance in the weight-loss market.",
      "url": "https://finnhub.io/api/news?id=d9f76ba284d8441ddf69772ab7bf1f4b6e667b52e96ca4a7d3c32fc823ed3c2e"
    },
    {
      "headline": "FDA targets more online vendors selling unapproved GLP-1RA products",
      "source": "Yahoo",
      "datetime": 1734525368,
      "summary": "Improper advertising on media constituted a large part of traffic directed to the companies\u2019 websites.",
      "url": "https://finnhub.io/api/news?id=e491a3bea9063ee53cb836abbbdc0350405129b4b2356daad62de862bcc9227e"
    },
    {
      "headline": "Pfizer: I'm Short-Term Skeptical, Long-Term Positive Post 2025 Guidance Call",
      "source": "SeekingAlpha",
      "datetime": 1734521024,
      "summary": "Pfizer\u00e2\u0080\u0099s financial challenges are offset by growth potential in oncology and strong dividends. Learn why PFE stock is a \"Buy\" as we look toward 2025.",
      "url": "https://finnhub.io/api/news?id=8f79def61af3be1708e5b903db4bf9729d73b4b340f50bbbac83940c1eaa95c5"
    },
    {
      "headline": "Ozempic Dethroned? A Head-to-Head Study Confirms This Company Has the Best Weight Loss Drug",
      "source": "Yahoo",
      "datetime": 1734520500,
      "summary": "When you think of a top weight loss drug, chances are that Ozempic is the name that first comes to mind.  Although it is approved for diabetes (Wegovy is the equivalent version, which is approved for weight loss), many people have been using it for years to lose weight, and it has been highly effect",
      "url": "https://finnhub.io/api/news?id=65e10557526be0928f39902bbd872ace0bf1683efb11236cabc87d426e04d1cb"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470584.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000291/xslF345X05/wk-form4_1734470584.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470498.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000289/xslF345X05/wk-form4_1734470498.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470366.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000287/xslF345X05/wk-form4_1734470366.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470270.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000285/xslF345X05/wk-form4_1734470270.xml"
    },
    {
      "form": "4",
      "date": "2024-12-17",
      "description": "xslF345X05/wk-form4_1734470180.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947824000283/xslF345X05/wk-form4_1734470180.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}